ALX Oncology Holdings Inc. (ALXO)
NASDAQ: ALXO · Real-Time Price · USD
0.4058
-0.0468 (-10.34%)
At close: Jun 27, 2025, 4:00 PM
0.4349
+0.0291 (7.17%)
After-hours: Jun 27, 2025, 7:48 PM EDT
ALX Oncology Holdings Employees
ALX Oncology Holdings had 80 employees as of December 31, 2024. The number of employees increased by 8 or 11.11% compared to the previous year.
Employees
80
Change (1Y)
8
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,625,288
Market Cap
21.69M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 80 | 8 | 11.11% |
Dec 31, 2023 | 72 | 14 | 24.14% |
Dec 31, 2022 | 58 | 15 | 34.88% |
Dec 31, 2021 | 43 | 20 | 86.96% |
Dec 31, 2020 | 23 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALXO News
- 4 weeks ago - ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - GlobeNewsWire
- 6 weeks ago - ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - GlobeNewsWire
- 7 weeks ago - ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - GlobeNewsWire
- 2 months ago - ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewsWire
- 2 months ago - ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints - GlobeNewsWire
- 4 months ago - ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire